Compare Samsara Inc (IOT) vs Eli Lilly And Co (LLY) Price & Performance

Samsara (IOT) trades at $41.71, up 2.96% with strong bullish momentum. The stock shows robust technical strength with bullish moving averages and trades near resistance at $42. Fundamentally, the company demonstrates impressive revenue growth, reaching $1.8B in 2026 with a positive net income turnaround to $91M. Recent Q2 2027 earnings beat expectations with $0.20 EPS versus $0.16 estimate, driven by 30% annual recurring revenue growth and expanding large-customer adoption.

Outlook remains positive with 75% analyst buy ratings and $51.15 consensus target, representing 23% upside. Key opportunities include enterprise standardization trends and AI integration through Samsara MCP. Risks include elevated valuation multiples (P/E 274.8, P/S 13.01) and potential cash flow pressure despite strong operational performance. The stock's recent 72% rally warrants monitoring for sustainability beyond multiple expansion.

Eli Lilly (LLY) trades at $1,188.72, up 2.7% today, reflecting strong momentum driven by robust earnings beats and bullish technical signals. The stock exhibits impressive fundamentals with 2025 revenue of $65.18B and net income of $20.64B, yielding a net margin of 31.66%. Recent news highlights promising pipeline developments in weight-loss drugs, including EloraTZP, which outperformed Zepbound in trials, reinforcing its competitive edge in the obesity and diabetes markets.

Outlook remains positive given analyst consensus of a $1,350 price target and 73% buy ratings, though high valuation multiples (P/E 39.26) and rising debt-to-asset ratios (42.78% in 2024) warrant caution. Key risks include regulatory hurdles and intensifying competition from rivals like Novo Nordisk, but Lilly's innovation pipeline and market leadership position it for sustained growth.